Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li(Johns Hopkins University), Nita Ahuja(Johns Hopkins University), Jianjun Luo(Institute of Biophysics), Hariharan Easwaran(Johns Hopkins University), Angela A. Guzzetta(Sidney Kimmel Comprehensive Cancer Center), Katherine B. Chiappinelli(George Washington University), Nancy E. Davidson(WinnMed), Rajita Vatapalli(AstraZeneca (United States)), Vered Stearns(Johns Hopkins University), Roisín M. Connolly(Johns Hopkins University), Stephen B. Baylin(Johns Hopkins University), Michael J. Topper(Johns Hopkins University), Nilofer S. Azad(Johns Hopkins Hospital), Drew M. Pardoll(Bloomberg (United States)), Peter A. Jones(Van Andel Institute), Ray-Whay Chiu Yen(Johns Hopkins University), Cynthia A. Zahnow(Johns Hopkins University), Dennis J. Slamon(University of California, Los Angeles)
Cited by 443
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k